Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 May 2017Website:
http://altimmune.comNext earnings report:
09 August 2024Last dividends:
20 January 2017Next dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:59:46 GMTDividend
Analysts recommendations
Institutional Ownership
ALT Latest News
NEW YORK, NY / ACCESSWIRE / July 4, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=89171&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / July 4, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=89141&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / July 4, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ:ALT) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Altimmune securities between December 1, 2023 and April 26, 2024, inclusive (the "Class Period").
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=89123&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds those who purchased common stock or purchased call options or sold put options, including any common stock purchased or otherwise acquired in connection with the exercise of such options of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the “Class Period”), of the important July 5, 2024 lead plaintiff deadline.
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=89118&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=88970&wire=1 or contact Joseph E. Levi, Esq.
Clinical-state biopharmaceutical company Altimmune Inc. NASDAQ: ALT focuses on developing peptide-based therapeutics for obesity and chronic liver diseases, including non-alcoholic steatohepatitis (NASH). Their top candidate is a GLP-1/glucagon agonist called pemvidutide.
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=88916&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=88910&wire=1 or contact Joseph E. Levi, Esq.
What type of business is Altimmune?
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
What sector is Altimmune in?
Altimmune is in the Healthcare sector
What industry is Altimmune in?
Altimmune is in the Biotechnology industry
What country is Altimmune from?
Altimmune is headquartered in United States
When did Altimmune go public?
Altimmune initial public offering (IPO) was on 26 May 2017
What is Altimmune website?
https://altimmune.com
Is Altimmune in the S&P 500?
No, Altimmune is not included in the S&P 500 index
Is Altimmune in the NASDAQ 100?
No, Altimmune is not included in the NASDAQ 100 index
Is Altimmune in the Dow Jones?
No, Altimmune is not included in the Dow Jones index
When does Altimmune report earnings?
The next expected earnings date for Altimmune is 09 August 2024